Table 1.

Ten Research Questions Prioritized by Gender Wellness Center Clinicians

(1) Is the age at which gender incongruence is first manifested predictive of its persistence/desistence?

(2) Is gender identity stability over time associated with a greater likelihood of persistent gender incongruence?

(3) Does bone density decrease among patients receiving GnRH analogs? And, does bone density return to normal expected levels after treatment with GAHT?

(4) How does expected height compare to actual height among children who receive GnRH analogs and GAHT?

(5) How do pretreatment hormone levels among transgender individuals compare to hormone level norms (matched for Tanner Stage and sex assigned at birth)? Are baseline testosterone levels higher among transgender men compared to norms?

(6) What is the prevalence of self-harm behaviors in this sample of youth?

(7) What is the prevalence of eating disorders in this sample of youth?

(8) Do psychological outcomes (i.e., depression) improve over the course of treatment?

(9) Are there any short-term or long-term adverse effects associated with the use of pubertal blockers and GAHT? Specifically, are there adverse effects associated with Lupron injections?

(10) How do GnRH analogs and/or GAHT affect BMI?

BMI, body mass index; GAHT, gender-affirming hormone therapy; GnRH, Gonadotropin Releasing Hormone.